June 23, 2025

Higher SCFAs in Blood Predict Diabetes Risk

New research following Spanish adults over 7 years found that higher levels of specific gut-derived fatty acids in the blood—especially butyrate and isobutyrate—were linked to an increased risk of developing type 2 diabetes, offering insights into early risk prediction.

Conexiant

June 23, 2025

Psoriasis Biologics May Reduce Heart Risks

A large international study found that psoriasis patients treated with biologic therapies had a significantly lower risk of cardiovascular disease compared to those receiving oral treatments.

Conexiant

June 20, 2025

Platelet Indices Signal Aspirin Resistance in Preeclampsia

New research links changes in platelet count and volume to aspirin nonresponsiveness in pregnant women who develop preeclampsia, offering insights into potential biomarkers for risk monitoring.

Conexiant

June 19, 2025

Is More Fiber the Heart’s Ally?

A long-term U.S. study found that greater adherence to a plant-based cholesterol-lowering diet was linked to lower cardiovascular, coronary heart disease, and all-cause mortality.

Conexiant

June 18, 2025

SGLT2 Inhibitor Empagliflozin Preserves Kidney Function After Heart Attack

A secondary analysis of the EMPACT-MI trial, published in Nature Cardiovascular Research, shows that the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin stabilizes kidney function and reduces heart failure hospitalizations in patients who have recently experienced a heart attack.

Conexiant

June 17, 2025

Global Study Maps Sex Differences in Care

A global study found sex differences in risk factors, care access, and mortality for hypertension, diabetes, and HIV, using comprehensive international datasets.

Conexiant

June 17, 2025

Is Stroke Risk Lower with Semaglutide?

Semaglutide lowered stroke risk compared to empagliflozin in adults with type 2 diabetes, though overall mortality and heart attack rates were similar between the two drugs.

Conexiant

June 17, 2025

Does Stopping Obesity Treatment Early Undermine Success?

A large real-world study found that early discontinuation of semaglutide or tirzepatide in patients with obesity led to significantly smaller reductions in body weight and HbA1c compared to patients who continued treatment.

Conexiant

June 16, 2025

Can One Drug Decode Obesity’s Roots?

A new treatment for rare, extreme hunger offers life-changing relief and uncovers clues to obesity’s tangled biology—reshaping how we understand and treat the condition.

KFF Health News